FDA unveils risk-management program for ESAs.
Kate
K
Traynor
D004345:Drug Industry; D004920:Erythropoiesis / Q000187:drug effects*; D004921:Erythropoietin / Q000009:adverse effects* / Q000627:therapeutic use*; D009369:Neoplasms / Q000150:complications / Q000473:pathology; D010607:Pharmacy Service, Hospital; D011994:Recombinant Proteins; D012308:Risk Management; D014481:United States; D014486:United States Food and Drug Administration
D011994:Recombinant Proteins; D004921:Erythropoietin